company tower banner
Maypro Company Logo

Nutiani HN019™

1 of 1 products in this brand
Supported by 35+ human clinical studies, Nutiani HN019 has been shown to support gut integrity and barrier functions in both young and older populations. Benefits include:• Promotes bowel movement by decreasing the intestinal transit time• Improves protection against diarrhea inducing pathogens• May reduce infection induced inflammation• May improve the availability of iron in the bodyManufactured in a proprietary method to increase stability and reduce the die-off rate, Nutiani HN019 is ideal for several formulations such as supplements, drink powder mixes, yogurts, and confectionaries.

Ingredient Name: Bifidobacterium Lactis

Functions: Probiotic

Labeling Claims: Halal, Kosher, Non-GMO, Vegan

Certifications & Compliance: Halal, Kosher, Vegan

Benefit Claims (Health): Anti-Inflammatory, Stimulates Immune System

    Knowde Enhanced TDS

    Identification & Functionality

    Ingredient Name
    Food Ingredients Functions
    Pharma & Nutraceuticals Functions
    Ingredients
    Bifidobacterium Lactis

    Features & Benefits

    Product Highlights
    • Researched in numerous human clinical studies with subjects ranging from the elderly, children, and infants.
    • A stable probiotic manufactured to reduce die off rate.
    • Can be formulated into supplements, yogurt, powdered beverages, confectionaries, and high fiber juices.
    Benefits of BifidoB HN019™
    • Promotes bowel movement by decreasing the intestinal transit time
    • Improves protection against diarrhea inducing pathogens
    • May reduce infection induced inflammation
    • May improve the availability of iron in the body

    Applications & Uses

    Regulatory & Compliance

    Certifications & Compliance

    Technical Details & Test Data

    Clinical Study of BifidoB HN019™

    Nutiani HN019™ - Clinical Study of Bifidob Hn019™

    Average and confidence interval of the AGACHAN score of constipated women self-reported at the basal week and after 4-weeks treatment with synbiotic (n-24) or placebo (n-26). Nonparametric ANOVA for repeated measures and Wilcoxon.